Skip to Content

Remifentanil Injection

Last Updated: September 17, 2018
Status: Current

Products Affected - Description
    • Ultiva lyophilized powder for injection, Mylan Institutional, 1 mg, vial, 10 count, NDC 67457-0198-03
    • Ultiva lyophilized powder for injection, Mylan Institutional, 2 mg, vial, 10 count, NDC 67457-0198-05
    • Ultiva lyophilized powder for injection, Mylan Institutional, 5 mg, vial, 10 count, NDC 67457-0198-10
    • Remifentanil lyophilized powder for injection, Fresenius Kabi, 1 mg, vial, 10 count, NDC 63323-0723-03
    • Remifentanil lyophilized powder for injection, Fresenius Kabi, 2 mg, vial, 10 count, NDC 63323-0724-05
    • Remifentanil lyophilized powder for injection, Fresenius Kabi, 5 mg, vial, 10 count, NDC 63323-0725-10
Reason for the Shortage
    • Mylan Institutional did not provide a reason for the shortage.
    • Fresnius Kabi launched generic remifentanil in January 2018.
Available Products
    • There is insufficient supply for usual ordering

Estimated Resupply Dates

    • Mylan Institutional has Ultiva 1 mg, 2 mg, and 5 mg vials on back order and the company estimates a release date of mid-October 2018 for the 1 mg and 2 mg vials and mid-November 2018 for the 5 mg vials.
    • Fresenius Kabi has remifentanil 1 mg, 2 mg, and 5 mg vials on back order and the company estimates a release date of late-September for the 1 mg and 2 mg vials and cannot estimate a release date for the 5 mg vials.

Updated

Updated September 17, 2018 by Michelle Wheeler, PharmD, Drug Information Specialist. Created January 2, 2018 by Michelle Wheeler, PharmD, Drug Information Specialist. Copyright 2018, Drug Information Service, University of Utah, Salt Lake City, UT.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide